Sort
53,477 grants matching “addiction”
Real time relapse risk scoring for Opioid Use Disorder (OUD) from clinical trial datasets
$650,581Sean Xiao Luo · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · R01 · FY2025 · DA
NOVEL PHARMACOTHERAPY FOR TREATMENT OF COCAINE ADDICTION
$650,551Frank I Carroll · Research Triangle Institute · U19 · FY2007 · DA
Rodent Drug Discrimination & Locomotor Activity Testing
$650,476Michael Forster · University Of North Texas Hlth Sci Ctr · N01 · FY2011 · DA
Evaluation of mechanistic role of artemin/GFRα3 signaling in osteoarthritis pain
$650,454Santosh K. Mishra · North Carolina State University Raleigh · R01 · FY2024 · AR
Abstinence-Contingent Wage Supplements for Long-Term Treatment of Drug Addiction
$650,448Kenneth Silverman · Johns Hopkins University · R01 · FY2016 · DA
Reducing Alcohol use among Elective Surgical Patients using Adaptive Interventions
$650,389Anne Christie Fernandez · University Of Michigan At Ann Arbor · R01 · FY2024 · AA
Disease Management for Smokers in Rural Primary Care
$650,259University Of Kansas Medical Center · R01 · FY2005 · CA
Neural mechanisms of motivational and cognitive impairment in opioid withdrawal
$650,250Sean Bjorn Ostlund · University Of California-Irvine · R01 · FY2025 · DA
Western States Node of the National Drug Abuse Treatment Clinical Trials Network
$650,185James L. Sorensen · University Of California, San Francisco · U10 · FY2011 · DA
A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders
$650,165Kyle Matthew Kampman · University Of Pennsylvania · UG1 · FY2023 · DA
Exploiting A Critical Vulnerability To Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)
$650,089Mark Yarchoan · Johns Hopkins University · R01 · FY2024 · CA
Selective Probes for Alpha9* Nicotinic Acetylcholine Receptors
$650,079Ganesh A Thakur · Northeastern University · R01 · FY2025 · NS
Therapeutic enzyme depletion of L-serine for cancer treatment
$650,029Everett Stone · University Of Texas At Austin · R01 · FY2023 · CA
PASSIVE IMMUNITY TO COCAINE USING NOVEL HUMAN ANTIBODIES
$650,000University Of Cincinnati · U19 · FY2003 · DA
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** THE LEAVES OF MITRAGYNA SPECIOSA (KRATOM), PRODUCE MORE THAN 50 MONOTERPENE INDOLE ALKALOIDS (MIAS) AND SPIROOXINDOLE ALKALOIDS ASSOCIATED WITH VARIED PHARMACEUTICAL USES. FOR EXAMPLE, THE MIA MITRAGYNINE HAS SHOWN PROMISE AS A POTENTIAL TREATMENT FOR PAIN, OPIOID USE DISORDER, AND OPIOID WITHDRAWAL WITHOUT ANY DEMONSTRATED ADDICTION POTENTIAL; AND THE SPIROOXINDOLE MITRAPHYLLINE SHOWS ANTI-TUMOR ACTIVITY. THE EXISTING KNOWLEDGE GAP IN THE BIOSYNTHESIS OF BIOACTIVE M. SPECIOSA ALKALOIDS PREVENTS SYSTEMATIC ADVANCES IN ENGINEERED PRODUCTION OF THESE HIGH VALUE COMPOUNDS, CREATING A BOTTLENECK FOR PHARMACEUTICAL RESEARCH AND PRODUCTION. THIS PROPOSAL COMBINES EXPERTISE OF AN INTERNATIONAL INTERDISCIPLINARY TEAM TO ELUCIDATE THE BIOSYNTHESIS OF MULTIPLE BIOACTIVE ALKALOIDS IN MITRAGYNA SPECIES.A MULTI-FACETED APPROACH INCORPORATING GENOMICS, TRANSCRIPTOMICS, AND METABOLOMICS WILL BE JOINTLY APPLIED TO GENERATE GENOMIC RESOURCES FOR MITRAGYNA SPECIES, INCLUDING GENOME AND TRANSCRIPTOME ASSEMBLIES AND ANNOTATION TO ENABLE PATHWAY DISCOVERY OF DIVERSE BIOACTIVE ALKALOIDS; AND ELUCIDATE THE BIOSYNTHESIS OF SELECTED PHARMACEUTICAL MIAS AND SPIROOXINDOLE ALKALOIDS. THE METABOLIC ENGINEERING AND FURTHER BIOSYNTHETIC UNDERSTANDING OF MITRAGYNA ALKALOIDS ENABLED BY THIS PROJECT ARE EXPECTED TO HAVE A SIGNIFICANT POSITIVE IMPACT TOWARDS THE MITIGATION OF THE OPIOID CRISIS IN THE U.S AND AROUND THE WORLD. IN ADDITION, GENOMIC RESOURCES GENERATED IN THIS PROJECT WILL BE AN INVALUABLE RESOURCE FOR THE SCIENTIFIC COMMUNITY IN MIA AND SPIROOXINDOLE ALKALOIDS RESEARCH.
$650,000University Of Florida · · FY2024 · National Institute of Food and Agriculture
PUBLISHING NIDA NOTES AND ADDICTION SCIENCE & CLINICAL PRACTICE, N02DA-9-2607
$649,895Don Enichen · Research Triangle Institute · N02 · FY2011 · DA
Stop-and-Frisk, Arrest, and Incarceration and STI/HIV Risk in Minority MSM
$649,885Maria Rabia Khan · New York University School Of Medicine · R01 · FY2021 · DA
Role of Health Care in Addressing Unhealthy Alcohol Use and Disparities among Aging Women
$649,854Cynthia I Campbell · Kaiser Foundation Research Institute · R01 · FY2024 · AA
Development of Pharmacotherapies for Nicotine Addiction
$649,807Research Triangle Institute · U19 · FY2005 · DA
Circadian rhythms and homeostatic sleep regulation during adolescence: Implications for reward, cognitive control, and substance use risk
$649,781Peter L Franzen · University Of Pittsburgh At Pittsburgh · P50 · FY2025 · DA
Drug Use, HIV, and Other Comorbidities In A Vulnerable Population
$649,685Susan D Cochran · University Of California Los Angeles · R01 · FY2007 · DA
Longitudinal Networks Core
$649,616Kimberly A Tyler · University Of Nebraska Lincoln · P20 · FY2025 · GM
A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain
$649,606Barth Lance Wilsey · University Of California, San Diego · R01 · FY2016 · DA
Amygdala Output Circuitry in Reward Encoding, Expectation, and Decision Making
$649,566Kate Wassum · University Of California Los Angeles · R01 · FY2024 · DA
TREATMENT AND OUTCOME OF EARLY ONSET BIPOLAR DISORDER
$649,551Long Island Jewish Medical Center · R01 · FY2002 · MH